EUVIMEDEUVIMED entdecken
Crossref

Is There a “Best” Way for Patients to Participate in Pharmacovigilance?

Austin Due

The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine · 2025

DOI: 10.1093/jmp/jhae038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine, 2025. Verfasst von Austin Due. Beteiligte Einrichtung: East Tennessee State University, Johnson City, Tennessee, USA. Hauptthemen laut MEDLINE: Patient Participation, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The underreporting of suspected adverse drug reactions hinders pharmacovigilance. Solutions to underreporting are oftentimes directed at clinicians and healthcare professionals. However, given the recent rise of public inclusion in medical science, solutions may soon begin more actively involving patients. I aim to offer an evaluative framework for future possible proposals that would engage patients with the aim of mitigating underreporting. The framework may also have value in evaluating current reporting practices. The offered framework is composed of three criteria that are bioethical, social-epistemic, and pragmatic: (i) patients should not be exposed to undue harms, for example, nocebo effects; (ii) data should be collected, analyzed, and communicated while prioritizing pharmacovigilance’s aims, that is, free from industry bias; and (iii) proposals should account for existing and foreseeable pragmatic constraints like clinician “buy in” and existing reporting infrastructure. Proposals to engage patients in pharmacovigilance that fulfil or address these criteria are preferable to those that do not.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient ParticipationPharmacovigilanceAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsHumans

Stichwörter der Autor:innen

citizen sciencenocebo effectsparticipatory researchpharmacovigilanceunderreporting

Autor:innen und Institutionen

  • East Tennessee State University, Johnson City, Tennessee, USA.

Zitieren

APA

Due, A. (2025). Is There a “Best” Way for Patients to Participate in Pharmacovigilance?. The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine. https://doi.org/10.1093/jmp/jhae038

Vancouver

Due A. Is There a “Best” Way for Patients to Participate in Pharmacovigilance?. The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine. 2025. doi:10.1093/jmp/jhae038

BibTeX
@article{Due2025,
  author = {Due, Austin},
  title = {Is There a “Best” Way for Patients to Participate in Pharmacovigilance?},
  journal = {The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine},
  year = {2025},
  doi = {10.1093/jmp/jhae038}
}
Kostenlos starten →